Navigation Links
Combination therapy packs 1-2 punch against melanoma
Date:6/1/2008

DURHAM, N.C. -- Disabling a protein frequently found in melanoma tumors may make the cancer more vulnerable to chemotherapy, according to a pilot study led by researchers in the Duke Comprehensive Cancer Center.

We tested a compound that can weaken the tumor by targeting a protein found on the surface of a melanoma cell," said Douglas Tyler, M.D., a surgeon at Duke and the Durham Veterans Affairs Medical Center, and senior investigator on this study. "When chemotherapy was applied to the tumor in this weakened state it was much more effective compared to conventional therapy alone.,

The researchers presented their findings June 1 in a poster discussion session at the American Society of Clinical Oncology annual meeting in Chicago. The study was funded by Adherex Technologies, the company developing the compound that was tested in combination with chemotherapy.

Sixteen patients received the therapy as part of this study. All had been diagnosed with regionally advanced, in-transit melanoma, characterized by cancerous growths that appear and spread mainly on the limbs. This type of melanoma is often treated with regional chemotherapy, where veins and arteries are accessed in the affected area and large doses of chemotherapy are pumped directly into the body. The patients on this study received a drug known as ADH-1 both before and after chemotherapy; ADH-1 makes it difficult for cells to properly bind to one another.

Eight of the patients on the study had complete responses to therapy, meaning their tumors completely disappeared, said Georgia Beasley, M.D., a medical student at Duke and lead investigator on the study. This is very encouraging and we look forward to continuing this study and then eventually moving on to a Phase III trial.

Regional infusion of chemotherapy for melanoma is given under surgical conditions. Without ADH-1, patients generally have complete responses about 25 to 35 percent of the time.

Compared to some previous data, we have been able to double the number of complete responders to therapy by adding the ADH-1, so thats extremely promising, Beasley said.

Melanoma often affects people on their extremities, with a common scenario being a mole that appears on the foot and then spreads up the leg.

These early results really speak to the importance of developing combination therapies, Beasley said. Earlier animal results showed that using ADH-1 alone was not an effective treatment, but in combination with chemotherapy the results, both pre-clinically and clinically, have been very exciting.

The incidence of malignant melanoma is increasing at a rate faster than any other cancer, with 60,000 new cases expected to be diagnosed this year in the United States. Melanoma that has spread beyond the primary site is rarely curable, and treatment options are limited; even when it is treated, the response rates are typically poor and most people die within six to nine months.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. New combination therapy safe, promising for melanoma patients
2. Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
3. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
4. New patient satisfaction study with budesonide/formoterol combination therapy
5. New drug combination brings 1-2 punch against acute leukemia
6. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
7. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
8. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
9. Double binding sites on tumor target may provide future combination therapy
10. Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
11. Do bacterial combinations result in enhanced cytokine production? No!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MA (PRWEB) , ... May 25, 2016 , ... ... Research Institute (WCRI) compare outcomes of injured workers across 15 states. The ... to work, earnings recovery, access to medical care, and satisfaction with medical care. ...
(Date:5/25/2016)... ... 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group has been presented ... Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies for 48 years, ... who knew him. The award named for him is not given every year, but ...
(Date:5/25/2016)... ... May 25, 2016 , ... Casa Velas, an adults-only boutique hotel in ... to complement its new wellness suites . The two 1,350 sq. ft. suites ... of special services and insuite amenities, from a custom soap selection and in-suite exercise ...
(Date:5/25/2016)... ... 2016 , ... Laser Skin & Wellness Center is excited to ... of female aging. The Juliet™ procedure helps to reverse the effects ... laxity, itchiness and pain have reported real relief from these and other problems by ...
(Date:5/25/2016)... ... May 25, 2016 , ... First Choice Emergency Room , ... Anh Tat Nguyen, as the Medical Director of its new DeSoto facility. , ... our new DeSoto location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... -- The global  reprocessed medical devices market ... according to a new study by Grand View Research, ... the lack of centralized support for waste disposal in ... for reprocessed medical devices market. Additionally, the long-term cost-efficiency ... the original device is the high impact rendering driver ...
(Date:5/22/2016)... -- DS Biopharma (DS) today announced ... DS102 in chronic obstructive pulmonary disease (COPD) patients ... Recent DS preclinical data suggests that ... has bronchodilatory, anti-inflammatory and anti-fibrotic properties in the ... publish further detail on these findings later in ...
(Date:5/20/2016)... 2016 The Biotech arena remains ... the industry is not far from recovering. There are ... the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ... ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... Sign up for your free trading alerts on these ...
Breaking Medicine Technology: